Working… Menu

Biomarker Analyses in Hepatocellular Carcinoma (HCC) Patients Treated With TheraSphere®

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03203837
Recruitment Status : Terminated (Funding Discontinued due to low accrual rate)
First Posted : June 29, 2017
Last Update Posted : September 9, 2020
BTG International Inc.
Information provided by (Responsible Party):
Robert Lewandowski, Northwestern University

Brief Summary:
To analyze specific angiogenic, inflammatory and immune profiles in hepatocellular carcinoma patients who undergo radioembolization.

Condition or disease Intervention/treatment
Hepatocellular Carcinoma Other: Plasma collection

Detailed Description:
Patients who have planned lobar radioembolization (TheraSphere (TS)) and consent to this study will have peripheral blood samples collected pre-TS, post-TS, 4 hours post-TS, 24 hours post-TS, 3 days post-TS, 7 days post-TS and 30 days post-TS to analyze specific angiogenic, inflammatory and immune profiles.

Layout table for study information
Study Type : Observational
Actual Enrollment : 4 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Biomarker Analyses in Hepatocellular Carcinoma Patients Treated With Therasphere®
Actual Study Start Date : July 5, 2017
Actual Primary Completion Date : January 6, 2020
Actual Study Completion Date : January 6, 2020

Group/Cohort Intervention/treatment
HCC patients
HCC patients treated with radioembolization. Plasma collection will be performed at 7 timepoints in relation to treatment.
Other: Plasma collection
We will be collecting plasma at 7 different timepoints in hepatocellular carcinoma patients that are treated with radioembolization.

Primary Outcome Measures :
  1. Percentage change in angiogenic, inflammatory and immune biomarkers [ Time Frame: 2 years ]
    The percent of change at 7 different timepoints for the following biomarkers will be calculated: Ang-2, FGFb, HB-EGF, HGF, PDGF-BB, PIGF, SDF-1, VEGF, VEGFC, IFNg, IL-1a, IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, TNFa trimer, CRP, TGFb1, EGFR, PD-1, PD-L1, CD45RA, CD127, HLA-DR, CD62L, CD3, CD8, CD197, CCR7, CD45RO, PD-L2, FOXP3, Perforin, Granzyme, TIA-1, CD14, CD107a, CD25, CD45, CD4, CD20 and CD56+16.

Secondary Outcome Measures :
  1. Treatment Response- AFP [ Time Frame: 2 years ]
    Alphafetoprotein will be measured in ng/mL.

  2. Treatment Response - Imaging [ Time Frame: 2 years ]
    Lesions will be measured using mRECIST.

  3. Treatment Response- Time-to-Progression [ Time Frame: 2 years ]
    Time-to-progression will be measured in days.

  4. Treatment Response- Overall Survival [ Time Frame: 2 years ]
    Overall survival will be measured in days.

Biospecimen Retention:   Samples With DNA
Any leftover patient plasma samples collected for this study will be retained for future research which may or may not involve genetic testing.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Patients diagnosed with hepatocellular carcinoma who will be receiving lobar TheraSphere radioembolization.

Inclusion Criteria:

  • Must have the diagnosis of HCC (biopsy or imaging criteria)
  • Must have planned lobar TheraSphere treatment
  • Must be able to give consent
  • Must have an ECOG (Eastern Cooperative Oncology Group) performance status of ≤ 2
  • Must have a life expectancy of ≥ 3 months
  • Women must not be pregnant with an acceptable contraception in premenopausal women
  • Must be > 4 weeks since prior radiation
  • Must be > 2 weeks since liver surgery
  • Must be ≥ 2 weeks post radiosensitizing chemotherapy or > 6 weeks since prior BCNU (carmustine) or Mitomycin-C

Exclusion Criteria:

  • Patients are excluded if they do not meet the inclusion criteria

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03203837

Layout table for location information
United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611
Sponsors and Collaborators
Northwestern University
BTG International Inc.
Layout table for investigator information
Principal Investigator: Robert Lewandowski, MD Northwestern University
Additional Information:

Layout table for additonal information
Responsible Party: Robert Lewandowski, MD, Northwestern University Identifier: NCT03203837    
Other Study ID Numbers: STU000201854
First Posted: June 29, 2017    Key Record Dates
Last Update Posted: September 9, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Robert Lewandowski, Northwestern University:
Prognostic factor
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases